ArticleClinical and translational medicine2021
Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab-paclitaxel in pancreatic cancer.
Zheng Zhang, Shunrong Ji, Qiangsheng Hu, Qifeng Zhuo, Wei Liu, Wenyan Xu, Wensheng Liu, Mengqi Liu, Zeng Ye, Guixiong Fan and 3 more
Open access · goldAbstract readCase ReportsLetter
In one paragraphArticle in Clinical and translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors at 1 institution in 1 country.
Zheng ZhangDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Shunrong JiDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID 0000-0003-2556-3320 Qiangsheng HuDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Qifeng ZhuoDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Wei LiuDepartment of Radiology, Fudan University Shanghai Cancer Center, Shanghai, China.
Wenyan XuDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Wensheng LiuDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Mengqi LiuDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Zeng YeDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Guixiong FanDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Xiaowu XuDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Xianjun YuDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID 0000-0002-6697-7143 Shanghai Medical College of Fudan University · CN
Funding
Clinical and Scientific Innovation Project of Shanghai Hospital Development Center SHDC12018109Clinical Research Plan of Shanghai Hospital Development Center SHDC2020CR1006ANational Natural Science Foundation 81871950National Natural Science Foundation 81972250National Natural Science Foundation 81972725National Science Foundation for Distinguished Young Scholars of China 81625016
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
AdenocarcinomaAlbuminsAntimetabolites, AntineoplasticAntineoplastic Agents, ImmunologicalBevacizumabCarcinoma, Pancreatic DuctalDeoxycytidineFatal OutcomeGemcitabineHumansMaleMiddle AgedPaclitaxelPancreatic NeoplasmsTreatment Outcome130-nm albumin-bound paclitaxelAlbuminsAntimetabolites, AntineoplasticAntineoplastic Agents, ImmunologicalBevacizumabDeoxycytidineGemcitabinePaclitaxel
Identifiers
PMID34459132
PMCPMC8387784
OpenAlexW3196698110
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390